Government greenlights nationwide hunt to cut apex predator population in half: 'We are concerned'
As Mongabay detailed, the Swedish government permitted a hunt in January that allowed for the killing of 30 endangered wolves. According to the Guardian, there were 375 recorded individuals before the hunt. Despite records that the population dropped around 20% in 2022-23, the government announced the intention to reduce numbers further.
The new "favorable conservation status" population number has been set at 170, down from the previous minimum of 300.
Bern Convention members also ruled recently that the wolves' status be moved from "strictly protected" to "protected," with this coming into force in March. This will enable more wolves to be legally culled in European nations. The ruling has been made to protect farmers' livestock and stop the wolf population from getting out of control.
However, according to the Guardian, environmental experts believe the ruling would not only be devastating for the wolves but for the wider ecosystem across the European continent as well.
For nearly 20 years and until 1983, Sweden had no wolf breeding population. With lax regulations and a hunting quota, the wolves are just barely getting by, the news outlet reported.
Ecosystems have a fragile balance. Without a top predator, prey species can over-populate, and the entire habitat can pay the price.
Unfortunately, the government gave the go-ahead and handed out permits to hunters, but this hasn't stopped protection efforts. Conservationists continue to speak out against the unnecessary killing of wolves.
A decade ago, similar outcry from conservationists, including the European Environmental Bureau and WWF, kept 44 wolves from being culled, showing action can yield results.
Should we be actively working to kill invasive species?
Absolutely
It depends on the species
I don't know
No — leave nature alone
Click your choice to see results and speak your mind.
If you're concerned about animal conservation where you live, you can donate to climate causes, or you can write to your local representative about the importance of healthy ecosystems.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
EU and US could reach trade deal this weekend
-- The European Union and the United States might reach a framework trade deal this weekend that would end months of uncertainty for European industry, according to a report from Reuters, citing EU officials and diplomats on Friday. The potential agreement would likely include a 15% baseline tariff on all EU goods entering the United States, with European steel and aluminum facing a probable 50% tariff, these sources said. U.S. President Donald Trump expressed caution about the prospects, stating on Friday that there was a "50-50 chance or perhaps less" of reaching a trade agreement with the European Union. He added that Brussels wanted to "make a deal very badly." One source indicated that a weekend deal appeared likely as the "agreement is basically in the hands of Trump now." There might also be a high-level meeting to finalize terms, as a source familiar with the negotiations mentioned there was a "good chance" European Commission President Ursula von der Leyen would meet Trump in Scotland over the weekend. A spokesperson for the European Commission did not respond to multiple requests for comment regarding a possible meeting between the leaders. Related articles EU and US could reach trade deal this weekend - Reuters Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse Surge of 50% since our AI selection, this chip giant still has great potential
Yahoo
5 hours ago
- Yahoo
Pharma braces for critical French drug pricing reforms pending CEPS's report
Growing budgetary pressure is a central theme in France as the country prepares for the publication of the government's 2026 Social Security Finance Bill (PLFSS). French Prime Minister François Bayrou has requested the Economic Committee for Health Products (CEPS) to create a report, which will be published by the end of July 2025 and released in Q3 2025, outlining its drug pricing policy recommendations. These policy recommendations are likely to be defined by what Bayrou describes as 'changing geopolitical context' and 'investment dynamics' for the EU pharma sector. The environment has therefore triggered an opportunity to re-evaluate current price setting and regulation policies, with the potential for greater flexibility and higher prices due to changing business conditions. This principle is already starting to be put in place. From March 2025, the CEPS has been required to consider the manufacturing location of production sites when setting prices, known as the 'industrial criterion'. While this policy existed previously, it is now mandated, giving preferential pricing for domestically manufactured medicines. A price premium for local manufacturing will likely improve the generic sector, making it more financially viable. Historically, financial viability has been a definitive struggle for generic and biosimilar manufacturers in France. Based on a sample of off-patent, generic, and biosimilar prices, these medicines are typically priced between 38% to 68% lower in France, on average, when compared to the other top European markets. Using the available current prices from GlobalData's Price Intelligence (POLI) & HTA service, the figure below compares the average price per milligram per unit of pack (one tablet, for example) difference between off-patent, generic, and biosimilar medicines that are available in France and the other four major European markets. The sample from each drug type was generated by including products that have their strength measured in milligrams and are available in all five markets. Figure 1: Average price per strength unit (euros/unit/mg) comparison of prices in France to the other EU5 market Furthermore, the Generic Same Drug Association (GEMME) in France has pushed for biosimilars to be excluded from the 'safeguard clause' pricing policy. This measure limits public health spending on medicines by requiring pharmaceutical companies to contribute to health spending once the reimbursed expense exceeds a set threshold. There may be further positive news for generics and biosimilars as the government also considers lowering the discount ceiling for generics from 40% down to 20%–25% while setting a low ceiling for biosimilars. While the upcoming report from CEPS will likely have benefits for the generic/biosimilar sector, it is unclear what potential benefits will be brought to the innovative pharmaceutical sector. There are appeals to change the 'safeguard clause' and lower the cap, and there are possible modifications, but it is unlikely to be entirely overhauled. It is more likely that other cost-saving measures will be considered. For example, medicines with low clinical value ratings (Service Médical Rendu, SMR) could be delisted. Products that are reimbursed at the lowest tier (15%) would therefore no longer be reimbursed. Such measures would likely target non-essential and lifestyle medicines that receive this low SMR rating in their cost-effectiveness assessments. GlobalData's Price Intelligence (POLI) & HTA service shows that 77 molecules are currently 15% reimbursed and could therefore face a delisting challenge. These products see an average first price cut similar to that of products with a higher clinical rating. The average first price cut across different reimbursement tiers ranges between 6% and 7% for the different clinical ratings. Therefore, products with a low clinical rating see a similar impact on price after launch compared to those with a higher rating, despite being more likely to have competition with alternative treatments on the market. Figure 2: Average first price cut (%) of products based on reimbursement level granted Additionally, France's National Health Insurance Agency (Caisse Nationale d'Assurance Maladie, CNAM) has set out proposals to save on pharmaceutical spending. In its annual report, CNAM suggested that medicines with an improvement in actual benefit (Amélioration du Service Médical Rendu, ASMR) that are rated 'absent/no improvement' (ASMR V) or 'minor' (ASMR IV) should be subject to a discount compared to the net price of the cheapest available comparator. The figure below shows the proportion of brands in France by ASMR ratings granted. More than 70% of brands, accounting for the majority of the medicines reimbursed in France, have been granted these ratings of ASMR IV or V and would therefore be impacted. Figure 3: Distribution of medicines in France by ASMR rating Throughout 2025, CEPS has been coordinating many policy initiatives that will determine and influence the government's approach to pharmaceutical spending in 2026. As such, the French Government has requested that the CEPS publish a report later in July 2025 to outline its policy recommendations. While this appears to be a quick turnaround for CEPS, the ongoing initial proposals have given a sneak peek into what this report may feature. The generic and biosimilar sectors are likely to benefit from upcoming reforms. Potential amendments could include changes to the limit discount ceiling and possible exclusion from the 'safeguard policy'. It is unclear what this report may consider for the innovative sector; however, certain medicines could be delisted based on reimbursement levels, and further discounts could be granted on net prices for products with ASMR IV and V ratings. This report will encompass the progress made for recent and upcoming policy actions, while also giving insight into significant spending constraints for innovative medicines expected for 2026. This article is produced as part of GlobalData's Price Intelligence (POLI) service, the world's leading resource for global pharmaceutical pricing, HTA and market access intelligence integrated with the broader epidemiology, disease, clinical trials and manufacturing expertise of GlobalData's Pharmaceutical Intelligence Center. Our unparalleled team of in-house experts monitors P&R policy developments, outcomes and data analytics around the world every day to give our clients the edge by providing critical early warning signals and insights. For a demo or further information, please contact us here. "Pharma braces for critical French drug pricing reforms pending CEPS's report" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Trump Says U.S. Has ‘50-50 Chance' of Reaching Trade Deal With EU
President Trump arrived in Scotland to meet the U.K. and the European Union leaders, saying the U.S. has a 'good, 50-50 chance' to strike a trade deal with the EU. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
